v3.26.1
Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Schedule of Acquisitions and Cost-Reduction/Productivity Initiatives (Detail) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended 27 Months Ended 33 Months Ended
Jun. 28, 2026
Jun. 29, 2025
Jun. 28, 2026
Jun. 29, 2025
Jun. 28, 2026
Jun. 28, 2026
Restructuring charges/(credits):            
Employee terminations $ 354 $ (148) $ 369 $ 236    
Asset impairments 54 44 82 217    
Exit costs 10 30 17 94    
Restructuring charges/(credits) [1] 419 (74) 468 547    
Integration costs and other [2] 38 56 89 113    
Restructuring charges and certain acquisition-related costs 457 (18) 557 660    
Inventory write-offs––recorded in Cost of sales 46 0 46 0    
Additional depreciation––asset restructuring recorded in Cost of sales [3] 10 4 14 7    
Implementation costs [4] 144 78 233 128    
Total costs associated with acquisitions and cost-reduction/productivity initiatives 653 54 848 727    
Biopharma [Member]            
Restructuring charges/(credits):            
Restructuring charges/(credits) 390 (406) 421 211    
Biopharma [Member] | Manufacturing Optimization Program [Member]            
Restructuring charges/(credits):            
Restructuring charges/(credits) (29) (408) (52) (412) $ 824  
Biopharma [Member] | Realigning Our Cost Base Program [Member]            
Restructuring charges/(credits):            
Restructuring charges/(credits) 417 (25) 464 562   $ 3,300
Income Statement Location [Axis]: us-gaap:CostOfGoodsAndServicesSold            
Restructuring charges/(credits):            
Implementation costs [4] 25 26 40 46    
Income Statement Location [Axis]: us-gaap:OtherNonoperatingIncomeExpense            
Restructuring charges/(credits):            
Net periodic benefit costs/(credits) recorded in Other (income)/deductions––net (5) (9) (2) (68)    
Income Statement Location [Axis]: us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost            
Restructuring charges/(credits):            
Implementation costs [4] 63 39 102 62    
Income Statement Location [Axis]: us-gaap:SellingGeneralAndAdministrativeExpense            
Restructuring charges/(credits):            
Implementation costs [4] $ 56 $ 14 $ 91 $ 20    
[1] Primarily represents cost-reduction initiatives. Amounts associated with our Biopharma segment: (i) charges of $390 million for the three months ended June 28, 2026 (including charges of $417 million for our Realigning our Cost Base Program and credits of $29 million for our Manufacturing Optimization Program), (ii) charges of $421 million for the six months ended June 28, 2026 (including charges of $464 million for our Realigning our Cost Base Program and credits of $52 million for our Manufacturing Optimization Program), (iii) credits of $406 million for the three months ended June 29, 2025 (including credits of $408 million for our Manufacturing Optimization Program and $25 million for our Realigning our Cost Base Program) and (iv) charges of $211 million for the six months ended June 29, 2025 (including charges of $562 million for our Realigning our Cost Base Program and credits of $412 million for our Manufacturing Optimization Program). For 2025, Employee terminations included revisions of estimates of previously recorded accruals for severance benefits, driven in large part by higher-than-expected voluntary attrition.
[2] Represents external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs.
[3] Represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.
[4] Represents incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.